| Literature DB >> 35855743 |
Mingchong Liu1, Chensong Yang1, Qining Chu2, Xiao Fu1, Yue Zhang1, Guixin Sun1.
Abstract
Background: Oxidative stress status may affect bone metabolism and regeneration. However, few studies reported whether oxidative stress could impact the outcomes of hip fractures. This study aimed to explore if superoxide dismutase and glutathione reductase, the critical antioxidant enzymes, correlated with the prognosis of hip fractures.Entities:
Keywords: glutathione reductases; hip fractures; oxidative stress; prognosis; superoxide dismutase
Mesh:
Substances:
Year: 2022 PMID: 35855743 PMCID: PMC9288178 DOI: 10.2147/CIA.S370970
Source DB: PubMed Journal: Clin Interv Aging ISSN: 1176-9092 Impact factor: 3.829
Figure 1Flowcharts of our study.
Baseline Characteristics of Patients Grouped by the Status of 1-Year Survival for Unmatched and PSM Population
| Variables | Unmatched Population | Matched Population | ||||
|---|---|---|---|---|---|---|
| Survival ≤ 1 Year (n=50) | Survival > 1 Year (n=251) | P-value | Survival ≤ 1 Year (n=46) | Survival > 1 Year (n=46) | P-value | |
| Demographic characteristics | ||||||
| Sex (female) | 40 (80.0%) | 173 (68.9%) | 0.116 | 37 (80.4%) | 37 (80.4%) | >0.999 |
| Age (years) | 83.48 ± 7.58 | 74.08 ± 9.84 | <0.001 | 83.37 ± 7.67 | 83.35 ± 7.30 | 0.760 |
| BMI (kg/m2) | 23.09 ± 3.35 | 23.10 ± 4.16 | 0.967 | 22.93 ± 3.22 | 23.42 ± 3.63 | 0.475 |
| Residence (rural) | 3 (6.0%) | 9 (3.6%) | 0.688 | 3 (6.5%) | 1 (2.2%) | 0.617 |
| Fractures history (yes) | 7 (14.0%) | 39 (15.5%) | 0.783 | 7 (15.2%) | 7 (15.2%) | >0.999 |
| Smoking history (yes) | 2 (4.0%) | 18 (7.2%) | 0.609 | 2 (4.3%) | 2 (4.3%) | >0.999 |
| Alcoholism history (yes) | 1 (2.0%) | 7 (2.8%) | 0.751 | 1 (2.2%) | 1 (2.2%) | >0.999 |
| Position of fracture (right) | 23 (46.0%) | 109 (43.4%) | 0.738 | 20 (43.5%) | 18 (39.1%) | 0.672 |
| Surgery-related variables | ||||||
| Location of fracture (transcervical) | 23 (46.0%) | 143 (57.0%) | 0.154 | 21 (45.7%) | 17 (37.0%) | 0.397 |
| Surgical procedures (arthroplasty) | 24 (48.0%) | 117 (46.6%) | 0.858 | 21 (45.7%) | 18 (39.1%) | 0.527 |
| Anesthesia (spinal) | 1 (2.0%) | 2 (0.8%) | 0.421 | 0 (0.0%) | 0 (0.0%) | >0.999 |
| Time from injury to surgery (Days) | 6.16 ± 4.71 | 5.63 ± 6.62 | 0.084 | 6.00 ± 4.77 | 4.93 ± 2.82 | 0.150 |
| CCI score (>4) | 15 (30.0%) | 48 (19.1%) | 0.084 | 13 (28.3%) | 14 (30.4%) | 0.819 |
| Electrocardiogram (abnormal) | 30 (60.0%) | 143 (57.0%) | 0.692 | 28 (60.9%) | 26 (56.5%) | 0.672 |
| Chest radiograph (abnormal) | 30 (60.0%) | 114 (45.4%) | 0.059 | 28 (60.9%) | 27 (58.7%) | 0.832 |
| Hypertension (yes) | 35 (67.0%) | 124 (49.4%) | 0.008 | 31 (67.4%) | 31 (67.4%) | >0.999 |
| Polytrauma (yes) | 5 (10.0%) | 29 (11.6%) | 0.752 | 4 (8.7%) | 4 (8.7%) | >0.999 |
| Laboratory findings | ||||||
| Hb (g/L) | 108.40 ± 21.37 | 116.24 ± 19.95 | 0.003 | 106.67 ± 19.79 | 103.39 ± 18.79 | 0.848 |
| INR | 1.04 ± 0.07 | 1.05 ± 0.14 | 0.538 | 1.04 ± 0.07 | 1.03 ± 0.09 | 0.576 |
| GLU (mmol/L) | 6.99 ± 2.96 | 6.71 ± 3.03 | 0.542 | 6.99 ± 3.03 | 6.96 ± 2.76 | 0.519 |
| ALB (g/L) | 36.88 ± 4.78 | 38.30 ± 4.32 | 0.066 | 36.76 ± 4.78 | 36.45 ± 3.86 | 0.584 |
| SOD (U/mL) | 116.66 ± 26.93 | 139.67 ± 27.89 | >0.001 | 116.13 ± 27.48 | 133.00 ± 29.40 | 0.026 |
| Glutathione reductase (U/L) | 53.04 ± 13.23 | 59.27 ± 12.28 | 0.003 | 54.04 ± 12.64 | 59.70 ± 10.39 | 0.021 |
Notes: Continuous variables were expressed as mean ± standard deviation and categorical variables were presented as count (percent).
Abbreviations: BMI, body mass index; Hb, Hemoglobin; INR, international normalized ratio; GLU, blood glucose; ALB, albumin; SOD, superoxide dismutase; GR, glutathione reductases.
Figure 2Serum levels of SOD and GR in the patients with Hip fracture after surgery grouped by one-year survival (A and B), and ROC curves of SOD and GR for one-year survival (C and D). (A and B) The patients who survived more than one year had significantly higher SOD levels (p = 0.026) than those who survived less than one year in the PSM population, as well as GR (p = 0.021); (C and D) Both SOD (AUROC: 0.635) and GR (AUROC: 0.640) were able to predict the 1-year survival according to the ROC curves.
Cox Regression Analyses of 1-Year Survival Adjusted for Different Factors
| Age | 1.077 (1.038, 1.117) | <0.001 | 1.077 (1.042, 1.113) | <0.001 |
| SOD (continuous) | 0.976 (0.965, 0.988) | <0.001 | 0.977 (0.966, 0.989) | <0.001 |
| GR (continuous) | 0.969 (0.944, 0.994) | 0.016 | 0.969 (0.945, 0.994) | 0.014 |
| Age | 1.078 (1.039, 1.118) | <0.001 | 1.077 (1.042, 1.112) | <0.001 |
| SOD (≤ 112.5 U/mL) | 2.965 (1.605, 5.476) | 0.001 | 2.690 (1.480, 4.890) | 0.001 |
| GR (≤ 52.5 U/L) | 2.991 (1.671, 5.355) | <0.001 | 2.736 (1.563, 4.792) | <0.001 |
Notes: Model 1 and Model 3 were adjusted for age, type of fracture, hypertension, Hb, CCI score, sex, time from injury to surgery, and ALB. Model 2 and Model 4 were fully adjusted. Continuous SOD and GR were analyzed in Model 1 and Model 2. Grouped SOD and GR were included in Model 3 and Model 4. Model 1 and Model 3 were direct entry models while Model 2 and Model 4 were conditional stepwise forward models.
Figure 3Kaplan–Meier analyses of one-year survival based on optimal serum levels of SOD (112.5 U/mL) and GR (52.5 U/L). (A) Kaplan–Meier analysis showed that SOD values of 112.5 U/mL significantly differentiated patients who died within one year and survived more than one year (p < 0.001), (B) SOD values of 52.5 U/L significantly differentiated patients who died within one year and survived more than one year (p < 0.001).
Comparison of Outcomes of All Patients in Our Study
| Outcomes | Total (N=458) | SOD | GR | ||||
|---|---|---|---|---|---|---|---|
| SOD ≤ 112.5 U/mL | SOD > 112.5 U/mL | P-value | GR ≤ 52.5 U/L | GR > 52.5 U/L | P-value | ||
| 3-month mortality | 9 (3.0%) | 5 (8.6%) | 4 (1.6%) | 0.018 | 7 (7.3%) | 2 (1.0%) | 0.008 |
| 6-month mortality | 16 (5.3%) | 9 (15.5%) | 7 (2.9%) | <0.001 | 12 (12.5%) | 4 (2.0%) | <0.001 |
| 1-year mortality | 50 (16.6%) | 23 (39.7%) | 27 (11.1%) | <0.001 | 28 (29.2%) | 22 (10.7%) | <0.001 |
| 3-month independent walking rate | 58 (19.3%) | 6 (10.3%) | 52 (21.4%) | 0.055 | 10 (10.4%) | 48 (23.4%) | 0.008 |
| 6-month independent walking rate | 164 (54.5%) | 17 (29.3%) | 147 (60.5%) | <0.001 | 36 (37.5%) | 128 (62.4%) | <0.001 |
| 1-year independent walking rate | 202 (67.1%) | 22 (37.9%) | 243 (74.1%) | <0.001 | 49 (51.0%) | 153 (74.6%) | <0.001 |
Logistics Regression for Mortalities at 6 Months and 1 Year and Free Walking Abilities at 6 Months and 1 Year
| 6-Month Mortality | 1-Year Mortality | 6-Month Free Walking Ability | 1-Year Free Walking Ability | |||||
|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | |
| SOD (continuous) | 0.975 (0.953, 0.997) | 0.025 | 0.975 (0.961, 0.989) | <0.001 | 1.016 (1.005, 1.026) | 0.003 | 1.017 (1.006, 1.028) | 0.003 |
| GR (continuous) | 0.929 (0.880, 0.979) | 0.006 | 0.964 (0.936, 0.992) | 0.012 | 1.037 (1.014, 1.061) | 0.002 | 1.043 (1.006, 1.028) | 0.001 |
| SOD (≤ 112.5 U/mL) | 4.071 (1.300, 12.751) | 0.016 | 3.613 (1.715, 7.609) | 0.001 | 0.416 (0.204, 0.847) | 0.016 | 0.331 (0.163, 0.673) | 0.002 |
| GR (≤ 52.5 U/L) | 7.193 (2.114, 24.475) | 0.002 | 3.613 (1.715, 7.609) | <0.001 | 0.354 (0.199, 0.631) | <0.001 | 0.316 (0.171, 0.583) | <0.001 |
Note: All models were conditional stepwise forward models and fully adjusted.